Company: Goldfinch Bio
Job title: Vice President of Translational & Clinical Nephrology
Liron Walsh comes to Goldfinch Biopharma with a Nephrology and Clinical Development background. Liron has held multiple clinical development leadership roles in both the Nephrology therapeutic area and the rare disease space.
Prior to joining Goldfinch, Liron served as a Senior Medical Director at BioMarin overseeing clinical development for two rare-disease programs; enzyme replacement therapy for Pompe’s Disease and gene therapy for Hemophila A. Liron was integral in advancing both programs, serving as the clinical lead for early and late phases of development. Prior to BioMarin, Liron was a Medical Director in the Nephrology therapeutic area at Amgen involved in the development of cinacalcet and etelcalcetide, calcimimetic agents for patients with chronic kidney disease. Liron oversaw multiple clinical studies at various stages of development, most notably, as the clinical lead for two phase 3 etelcalcetide clinical studies, which ultimately led to a successful approval in the US and the EU.
Liron received his MD from the University of Toronto and completed his Nephrology fellowship at Mount Sinai in NY in 2010.
Panel Discussion: Executing Precision Medicine in Clinical Trials 2:45 pm
day: Day One
Targeting FSGS as an Entry Point in CKD: Expanding From a Smaller Market 4:30 pm
day: Day One